Abbreviations: FAB ¼ French-American-British; CMV ¼ cytomegalovirus; ALL ¼ acute lymphoblastic leukemia; AML ¼ acute myeloid leukemia; sAML ¼ MDS-related secondary acute myeloid leukemia; CR1 ¼ first complete remission; PIF ¼ Primary induction failure.
We report a retrospective analysis of results of unrelated cord blood transplantation (CBT) after myeloablative conditioning in 11 patients with acute leukemia aged between 50 and 55 years. Recently, unrelated CBT has demonstrated promising results in adults. [1] [2] [3] [4] [5] [6] [7] [8] Although we have previously reported that unrelated CBT after myeloablative conditioning is feasible in patients over the age of 45 years, 4 there have been no reports detailing the data of more advanced age group. Between March 2000 and April 2005, 11 patients with acute leukemia over the age of 50 years were treated with unrelated CBT. The upper age limit for myeloablative conditioning is 55 years old. Analyses of data were performed on 1 September 2005. The characteristics of the 11 patients and cord blood units are shown in Tables 1 and 2 . Six patients included in our previous study were also included with an extended follow-up (cases 1-4, 7, 8) . [2] [3] [4] [5] Written informed consent for treatment was obtained from all patients. Cord blood unit was selected according to the number of nucleated cells per recipient's weight and HLA compatibility (HLA-A and -B by serology and HLA-DRB1 high-resolution DNA typing). Preferred cord blood units matched three or more of six HLA loci and contained a minimal cell count of 2 Â 10 7 nucleated cells/kg before freezing. All patients received 12 Gy total body irradiation (TBI) and chemotherapy as myeloablative conditioning. All but one patient received four fractionated 12 Gy TBI on days À9, À8 or days À8 and À7. Cytosine arabinoside (Ara-C) was administered intravenously over 2 h at a dose of 3 g/m 2 every 12 h on days À6 and À5 or days À5 and À4 (total dose 12 g/m 2 ). Recombinant human granulocyte colony-stimulating factor (G-CSF; lenograstim) was administered by continuous infusion at a dose of 5 mg/kg/day. Infusion of G-CSF was started 12 h before the first dose of Ara-C and stopped at the completion of the last dose. Cyclophosphamide (CY) was administered intravenously over 2 h at a dose of 60 mg/kg once daily on days À4 and À3 or days À3 and À2 (total dose 120 mg/kg). One patient (case 1), who had ALL, received four fractionated 12 Gy TBI on days À9 and À8, and CY was administered intravenously over 2 h at a dose of 60 mg/kg once daily on days À3 and À2 (total dose 120 mg/kg). Two days or 3 days after the completion of conditioning, patients received a CBT. All patients received standard cyclosporine (CyA) and methotrexate (MTX) as a graftversus-host disease (GVHD) prophylaxis. Cyclosporine was given every day starting on day À1 at a dose of 3 mg/kg/day. Methotrexate (15 mg/m 2 intravenously) was given on day 1, and 10 mg/m 2 on days 3 and 6. Both acute and chronic GVHD were graded according to the previously published criteria. The probability of diseasefree survival (DFS) was estimated by the Kaplan-Meier method. Among the patients the median age was 51 years (range, 50-55 years), the median weight was 59 kg (range, 44-64 kg) and the median number of cryopreserved nucleated cells was 2.50 Â 10 7 /kg (range, 2.05-3.53 Â 10 7 / kg). All but one patient had myeloid reconstitution and median time to more than 0.5 Â 10 9 /l absolute neutrophil count was 19.5 days (range, 18-25 days). A self-sustained platelet count more than 50 Â 10 9 /l was achieved in nine patients at a median time of 42 days (range, 33-88 days). Acute GVHD occurred in nine of 10 evaluable patients. The grading of acute GVHD was grade I in five patients and grade II in four. Among four grade II acute GVHD With a median follow-up of 749 days, the probability of DFS at 2 years was 72.7%. As previously described, 2-6 the lower transplantation-related mortality may be associated with a low incidence of severe acute GVHD in our patients. The lower genetic diversity of the Japanese population might explain the reason for there being relatively little severe acute GVHD. Although the number of patients was small and the observation period was limited, these results suggest that CBT after myeloablative conditioning may be feasible in patients with acute leukemia aged between 50 and 55 years. Abbreviations: GVHD ¼ graft-versus-host disease; NE ¼ not evaluable. Neutrophil recovery was defined as the first of three consecutive days during which the absolute neutrophil count in the blood was at least 0.5 Â 10 9 /l. Platelet recovery was defined as the first of three consecutive days during which the platelet count in the blood was at least 50 Â 10 9 /l without transfusion support. Hemoglobin level (8.5 g/dl) recovery was defined as the first of seven consecutive days without transfusion support. a Eight patients are alive in complete remission at the time of writing. Case 1, 5 and 8 relapsed on day 78, day 76 and day 53, respectively.
